Grant backed TILT Biotherapeutics has secured multi-million funding rounds, including a $23.7M round in early 2023 and a $12.8M round in 2023, plus a $2M DoD grant in 2024, indicating strong investor confidence and potential for grant-aligned partnerships or co-development funding opportunities.

Clinical collaboration The company actively collaborates with industry leaders (notably Merck) and operates multiple Phase I trials, signaling openness to alliance partnerships, licensing discussions, and strategic co-development opportunities to advance their oncolytic virus and TIL/CAR-T/immunotherapy platforms.

US expansion Recent office expansion to Boston reflects a growing US clinical development and partnering footprint, presenting sales opportunities for CROs, contract manufacturing, and clinical services aligned with their oncology programs.

Asset focus Lead candidate TILT-123 is a TNFα/IL2 armed oncolytic adenovirus with potential to enhance various immunotherapies, offering a clear entry point for service providers, diagnostic collaborators, and platform licensing negotiations around viral vector technologies.

Financial stability With a funding total around $25M and a zero to minimal revenue base, TILT presents opportunities for non-dilutive grants, venture debt, or milestone-based partnerships to advance ongoing Phase I programs and expand clinical/operational capabilities.